Is single-dose postoperative intravesical gemcitabine effective to prevent recurrence in patients with non-muscle invasive bladder cancer?

Is single-dose postoperative intravesical gemcitabine effective to prevent recurrence in patients with non-muscle invasive bladder cancer?

Bibliographic Details
Main Authors:	Abhishek Jain, Apul Goel, S N Sankhwar
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2010-01-01
Series:	Indian Journal of Urology
Online Access:	http://www.indianjurol.com/article.asp?issn=0970-1591;year=2010;volume=26;issue=1;spage=153;epage=155;aulast=Jain

Similar Items

Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review
by: Mi Ah Han, et al.
Published: (2021-11-01)

Bladder wall thickness for the assessment of voiding dysfunction
by: Abhishek Jain, et al.
Published: (2010-01-01)

Intravesical Gemcitabine versus Intravesical Bacillus Calmette–Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity
by: Thiru Prasanna, et al.
Published: (2017-11-01)

Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma
by: Zheng Du, et al.
Published: (2022-12-01)

Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy: A novel approach of treatment
by: Rohit Kathpalia, et al.
Published: (2011-01-01)

Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial
by: Rongxin Li, et al.
Published: (2020-07-01)

Role of plasma fibrinogen and D-dimer as prognostic biomarkers in patients with non-muscle invasive bladder cancer
by: Sahil Singla, et al.
Published: (2023-03-01)

Complete response to intravesical gemcitabine in non‐muscle invasive bladder cancer patient after BCG failure: A case report and literature review
by: Fouad Nahhat, et al.
Published: (2022-09-01)

Efficacy of intravesical therapies on the prevention of recurrence and progression of non‐muscle‐invasive bladder cancer: A systematic review and network meta‐analysis
by: Jun‐Lin Lu, et al.
Published: (2020-11-01)

Research progress in intravesical instillation for non-muscle invasive bladder cancer
by: Yang Haihong, Shang Panfeng, Liu Jianbing
Published: (2023-09-01)

Human alpha-lactalbumin made lethal to tumors: Can it be a new intravesical therapy for bladder cancer?
by: Amod Kumar Dwivedi, et al.
Published: (2010-01-01)

PemBla: a Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer
by: Woodcock, VK, et al.
Published: (2023)

PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non‐muscle‐invasive bladder cancer
by: Victoria K. Woodcock, et al.
Published: (2023-05-01)

TERT C228T mutation in non‐malignant bladder urothelium is associated with intravesical recurrence for patients with non‐muscle invasive bladder cancer
by: Yujiro Hayashi, et al.
Published: (2020-10-01)

The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: A pilot study
by: Pawan Vasudeva, et al.
Published: (2008-01-01)

The different predictive value of mean platelet volume-to-lymphocyte ratio for postoperative recurrence between non-muscular invasive bladder cancer patients treated with intravesical chemotherapy and intravesical chemohyperthermia
by: Chengbo Wang, et al.
Published: (2023-01-01)

Current intravesical therapies BCG-failure in non-muscle-invasive bladder cancer
by: Yunus Emre Göğer, et al.
Published: (2021-10-01)

Thermal Intravesical Chemotherapy Reduce Recurrence Rate for Non-muscle Invasive Bladder Cancer Patients: A Meta-Analysis
by: Kang Liu, et al.
Published: (2020-02-01)

The Role of Adjuvant Single Postoperative Instillation of Gemcitabine for Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
by: Georgios Koimtzis, et al.
Published: (2022-05-01)

Androgen receptor: A novel molecular tool for control of bladder cancer
by: Vengetesh K Sengottayan, et al.
Published: (2010-01-01)

Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence
by: Tian-Wei Wang, et al.
Published: (2019-10-01)

Continuous saline bladder irrigation for two hours following transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer does not prevent recurrence or progression compared with intravesical Mitomycin-C
by: Andrew T. Lenis, et al.
Published: (2018-10-01)

Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: Experience over the last decade
by: Sunny Goel, et al.
Published: (2019-07-01)

Difference in recurrence frequencies of non-muscle-invasive-bladder tumors depending on optimal usage of intravesical immunotherapy of bacillus Calmette-Guérin
by: Milošević Radovan, et al.
Published: (2015-01-01)

HER-2 overexpression is a negative predictive factor for recurrence in patients with non-muscle-invasive bladder cancer on intravesical therapy
by: Georgios Moustakas, et al.
Published: (2020-01-01)

Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer
by: Yu-Ching Wen, et al.
Published: (2021-01-01)

Prediction of intravesical recurrence of non-muscle-invasive bladder cancer by evaluation of intratumoral Foxp3+ T cells in the primary transurethral resection of bladder tumor specimens.
by: Ryosuke Murai, et al.
Published: (2018-01-01)

Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning
by: Kelly Ward, et al.
Published: (2022-07-01)

Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer
by: Christopher James, et al.
Published: (2023-04-01)

Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy
by: Vincenzo Serretta, et al.
Published: (2015-01-01)

Laboratory predictors to intravesical BCG therapy response in patients with non-muscle invasive bladder cancer
by: S. Yu. Konyashkina, et al.
Published: (2023-01-01)

Neoadjuvant systemic and intravesical chemotherapy with partial cystectomy for muscle invasive bladder cancer with concomitant CIS
by: Benjamin D. Plambeck, et al.
Published: (2023-09-01)

Comparison of sterile water irrigation versus intravesical mitomycin C in preventing recurrence of nonmuscle invasive bladder cancer after transurethral resection
by: Priyank Bijalwan, et al.
Published: (2017-01-01)

Expression of L-Type Amino Acid Transporter 1 is a Predictive Biomarker of Intravesical Recurrence in Patients with Non-Muscle Invasive Bladder Cancer
by: Sawazaki H, et al.
Published: (2021-08-01)

Evaluation of thermal dose effect in radiofrequency-induced hyperthermia with intravesical chemotherapy for nonmuscle invasive bladder cancer
by: Iris S. G. Brummelhuis, et al.
Published: (2023-12-01)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
by: Hyun Hwan Sung, et al.
Published: (2022-03-01)

The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer
by: Jian-Xin Chen, et al.
Published: (2023-10-01)

Clinical application and efficacy analysis of partial cystectomy combined with intravesical chemotherapy in muscle-invasive bladder cancer
by: Bin Zhang, et al.
Published: (2023-05-01)

Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer
by: Azharuddin Mohammed, et al.
Published: (2017-12-01)

Role of 5-alpha reductase inhibitors in the prevention of prostate cancer
by: Bhupendra P Singh, et al.
Published: (2011-01-01)